Junto Capital Management LP Sells 942,842 Shares of Boston Scientific Corporation $BSX

Key Points

• Junto Capital Management LP has reduced its holdings in Boston Scientific Corporation by 84.9%, now owning 168,254 shares after selling 942,842 shares in the first quarter.
• Baird Financial Group Inc. and other institutional investors have increased their positions in Boston Scientific, highlighting increased interest from various investment entities.
• Boston Scientific reported a quarterly earnings per share (EPS) of $0.75, exceeding expectations, while revenue reached $5.06 billion, marking a 22.8% increase year-over-year.

Junto Capital Management LP lessened its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 84.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 168,254 shares of the medical equipment provider's stock after selling 942,842 shares during the period. Junto Capital Management LP's holdings in Boston Scientific were worth $16,973,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the period. Highview Capital Management LLC DE boosted its holdings in Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares during the period. Rehmann Capital Advisory Group boosted its holdings in Boston Scientific by 6.9% in the fourth quarter. Rehmann Capital Advisory Group now owns 5,245 shares of the medical equipment provider's stock worth $468,000 after purchasing an additional 339 shares during the period. Finally, Freestone Grove Partners LP acquired a new position in Boston Scientific in the fourth quarter worth $26,702,000. Institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on BSX shares. Citigroup reissued a "buy" rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Barclays lifted their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, Truist Financial lifted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $117.50.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,214 shares of company stock valued at $13,125,957 over the last ninety days. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

BSX traded up $0.72 on Wednesday, hitting $107.38. The company had a trading volume of 7,550,493 shares, compared to its average volume of 7,485,579. The company's fifty day moving average price is $104.65 and its 200 day moving average price is $102.14. Boston Scientific Corporation has a 1-year low of $80.50 and a 1-year high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a market cap of $159.10 billion, a price-to-earnings ratio of 63.91, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the company earned $0.62 EPS. The company's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.